Stryker Corporation (SYK)
NYSE · Kalamazoo, Michigan, USA · Founded 1941 · CEO Kevin Lobo
Valuation summary
$223.06 fair value versus $313.08 in the market, a difference of -28.7%. Rated Reduce.
| Fair value per share | $223.06 |
| Current share price | $313.08 |
| Upside / downside | -28.7% |
| Bear case | $133.12 |
| Bull case | $356.31 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.70% |
| Market capitalisation | $119B |
| EV / Sales | 5.0x |
About Stryker Corporation
Founded in 1941 by orthopaedic surgeon Homer Stryker, who invented better hospital beds and surgical tools because the existing ones frustrated him. Kevin Lobo has been CEO since 2012. Stryker makes orthopaedic implants, surgical equipment and neurotechnology products, and its Mako robotic surgery platform has become the leading system for joint replacement. Once a hospital installs a Mako, it buys Stryker implants — an unusually effective razor-and-blade structure.
Investment case
- Mako robotic platform drives implant pull-through and locks in hospital accounts.
- Ageing demographics guarantee rising joint replacement procedure volumes for decades.
- One of the most consistent organic growth records in medical devices.
Key risks
- Hospital capital equipment budgets tighten when health systems come under financial pressure.
- Implant pricing faces steady downward pressure from hospital purchasing groups.
- Consistently expensive relative to medical device peers.
Recent developments
- 2026-10-30 · Shares fall about 10% as Q3 revenue of $6.52bn misses despite 7.7% organic growth; 2026 adjusted EPS guided to $14.80-$14.90 source
Revenue by segment
| MedSurg & Neurotechnology | 57% |
| Orthopaedics | 33% |
| Spine & Other | 10% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $28.1B | $3.9B |
| Year 2 | $30.3B | $4.3B |
| Year 3 | $32.7B | $4.7B |
| Year 4 | $35.2B | $5.1B |
| Year 5 | $38.0B | $5.6B |
What the street says
Regarded as the best growth compounder in medical devices, but the shares fell about 10% on 30 October 2026 after third-quarter revenue of $6.52bn missed estimates despite 7.7% organic growth, and the 2026 EPS guide of $14.80-14.90 came in below consensus as hip and knee growth slowed. The pushback has moved from valuation alone to whether orthopaedics growth is cooling.
Comparable companies: AZN · MDT · ABT · SNY · BSX · TMO · MRK · A
Open the interactive model, price chart and sensitivity grid →